Auro Laboratories Ltd's earnings have grown by 60.2%, whereas share price has appreciated 23.4% CAGR over the past five years, indicating the company’s share price is likely undervalued. However, for specific investment actions please consult your investment advisor.
Auro Laboratories Ltd share price has appreciated 35.5% annually (CAGR) over the past ten years.
Data is not available for this company.
Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah.
Companyâ€™s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on
Companyâ€™s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on 14th July, 1992. The manufacturing facility has an installed capacity in excess of 500 tonnes per annum.
Company is primarily focused on manufacturing anti-diabetic drugs. Presently company caters its products in therapeutic segment such as antihistamine, anti-fungal, anti-ulcer, anti-malaria, anti-inflammatory, antacids and others. Company exports its products in countries like Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. Auro Laboratories received ISO 9001:2000 and WHO - cGMP certifications for its quality management.
APIs- Under this company manufactures drugs like Chlorpheniramine Maleate, Chlorzoxazone, Metformin HCl, Potassium Iodate, Magnesium Hydroxide and many more.
Under specialty chemicals company manufactures Guanidine Nitrate, Dimethyl Amine HCl, 2-Ethoxy Benzoic Acid and 3,4,5, Trimethoxy Benzoic Acid.
Intermediate- Company manufactures products such as Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, Cis-bramo benzoate, 3, 4, 5 - Trimethoxy Benzoic Acid, 2-Ethoxy Benzoic Acid and 5-Bromo Phthalide
1992- Company started manufacturing of Sodium Citrate and Potassium Iodide. Company developed antibacterial drug, Trimethoprim.
1996- Company commenced manufacturing of 3,4,5 Trimethoxy Benzaldehyde, which is the basic raw material for Trimethoprim. Company was listed on Bombay Stock Exchange (BSE).
2004-Company received ISO 9001:2000 certification.
2006-Company received certificate of suitability (cos) from the European Directorate of Quality Medicine (EDQM).
2007- Company received DMF No 19910 from the FDA for Metformin Hydrochloride.
Future plansAuro Laboratories plans to widen its product portfolio to strengthen its position in the market.